dm+d
Unassigned
New Medicines
Lewy body and Parkinson's disease dementia
Information
New molecular entity
Eisai
Eisai
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
Phosphodiesterase 9 inhibitor
Incidence and prevalence figures vary widely, but a recent review in the UK found the incidence to be around 4% of new cases of dementia. It found DLB to account for 4.2% of all cases of dementia diagnosed in the community, and 7.5% of those diagnosed in secondary care [1].
Lewy body and Parkinson's disease dementia
Oral